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CDC TRIALS:
Pre-Exposure Prophylaxis for HIV Prevention
PrEP: A New Approach to HIV Prevention
New tools to prevent HIV are urgently needed to stem the estimated 2.6 million new HIV infections that occur worldwide each 
year. Recent research has shown that a new approach called pre-exposure prophylaxis, or PrEP, can reduce the risk of contracting 
HIV in gay and bisexual men at high risk of infection, when combined with existing prevention measures. Ongoing studies are 
evaluating this approach in other populations at risk for HIV, including heterosexuals and injection drug users. 
In this new approach to HIV prevention, people who are uninfected take an HIV treatment pill daily to reduce their risk of 
becoming infected. By inhibiting HIV from replicating as it enters the body, PrEP can prevent the virus from establishing 
permanent infection. The concept of providing a preventative treatment before exposure to an infectious agent is not new. 
For example, when individuals travel to an area where malaria is common, they are advised to take malaria treatment 
medication before and during travel to prevent illness.
As part of its commitment to developing new HIV prevention strategies, the Centers for Disease Control and Prevention 
has sponsored several clinical trials to evaluate the safety and efficacy of PrEP for HIV prevention. 
PrEP Medications
Current PrEP trials, including those sponsored by CDC, are testing the antiretroviral 
drug tenofovir disoproxil fumarate (or tenofovir, brand name Viread®) used alone or in 
combination with emtricitabine (together, known as the brand name Truvada®) taken as 
a preventative drug. 
Tenofovir was approved by the U.S. Food and Drug Administration in 2001 as a 
treatment for HIV infection, and the tenofovir plus emtricitabine combination pill 
was approved for use as an HIV treatment in 2004. Data from Gilead Sciences, Inc., 
the manufacturer of the drugs, indicate that more than one million HIV-infected 
people around the world have now used these drugs. As treatments for HIV-infected 
individuals, tenofovir and tenofovir plus emtricitabine have been shown to be both safe 
and effective. They have relatively low levels of side effects and slow development of 
associated drug resistance, compared with other available HIV treatments. 
Characteristics 
of Current PrEP 
Candidates
r  Established safety as HIV 
treatments
r Potent antiretrovirals
r Long duration of action
r Once-daily dosing
r Low levels of resistance
PrEP Proven Safe and Effective in Gay and Bisexual Men
In a major advance in HIV prevention research, investigators recently reported that PrEP is safe and effective in 
preventing HIV infection — when combined with other comprehensive prevention approaches — among men who have 
sex with men who are at high risk of HIV infection. 
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iPrEx Study
In November 2010, the National Institutes of Health (NIH) announced results from a multinational,  
randomized, double-blind, placebo-controlled, phase III clinical trial of tenofovir plus emtricitabine to prevent HIV infection.
The iPrEX trial showed that a once-daily pill containing tenofovir plus emtricitabine was safe and provided an average of 
44 percent additional protection against HIV infection to men who have sex with men and transgendered women who 
have sex with men, who also received a comprehensive package of prevention services. These services included use of 
condoms, monthly HIV testing, counseling to reduce risk behavior and encourage adherence to the daily pill regimen, 
and management of other sexually transmitted infections. 
The level of protection shown varied widely depending on how consistently participants used PrEP. Among those whose 
data (based on self-reports, bottles dispensed, and pill counts) indicate use on 90 percent or more days, HIV risk was 
reduced by roughly 73 percent, while among those whose adherence by the same measure was less than 90 percent, HIV 
risk was reduced by only about 21 percent. 
CDC U.S. Tenofovir Extended Safety Trial
In July 2010, CDC reported results of a Phase II extended safety trial examining the clinical and behavioral safety of once-
daily oral PrEP with tenofovir and adherence to the drug among gay and bisexual men in the United States. 
The study was conducted at three sites in collaboration with the San Francisco Department of Public Health, the AIDS 
Research Consortium of Atlanta, and Fenway Community Health in Boston. The study enrolled 400 HIV-negative MSM 
who reported having had anal intercourse with a man in the prior 12 months. Participants were randomly assigned to one 
of four study arms. Two arms received either tenofovir or placebo immediately upon enrollment, while the other two arms 
received either tenofovir or placebo after nine months of enrollment. This design allowed researchers to compare risk 
behaviors among those taking a daily pill and those not taking pills.
Preliminary analyses suggest no serious safety concerns. While analysis of behavioral safety data are not yet complete, 
preliminary analyses suggest there was no increased risk in men taking a study pill compared to those not taking a study pill 
during their first nine months of study participation. Additional analyses of clinical, behavioral, and adherence data are underway.
CDC-Sponsored PrEP Trials—Botswana and Thailand
CDC is sponsoring additional clinical trials that are 
designed to answer important questions about the safety 
and efficacy of a tenofovir or tenofovir plus emtricitabine 
pill taken as a daily oral HIV preventative among 
populations at high risk for infection — heterosexuals 
in Botswana and injection drug users in Thailand. Both 
trials are assessing the effects of taking a daily pill on 
HIV risk behaviors, adherence to and acceptability of the 
regimen, and in cases where participants become HIV-
infected, the resistance characteristics of the acquired 
virus. Importantly, the trial in Thailand will also examine 
the efficacy of PrEP in preventing HIV infection among 
injection drug users. 
CDC Study Botswana Thailand
Objective
Evaluate clinical and 
behavioral safety of 
and adherence to 
PrEP regimen among 
heterosexuals 
Evaluate PrEP safety  
and efficacy among 
intravenous drug users 
(IDUs)
Drug





heterosexual men and 
women in urban areas
2,400 HIV-negative IDUs 
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Trial Design and Procedures
Both of CDC’s current PrEP studies are randomized, double-blind, placebo-controlled trials. All participants  
receive risk-reduction counseling and other prevention services. Half of the participants are randomly assigned to receive 
one antiretroviral pill daily (either tenofovir or tenofovir plus emtricitabine, depending on the trial), and the other half 
are randomly assigned to take one placebo pill daily (a similar tablet without active medication). Neither researchers nor 
participants know an individual’s group assignment. In all, the studies involve approximately 3,600 volunteers. 
To make sure that participants fully understand all aspects of their participation, all volunteers are required to pass a 
comprehension test prior to providing written informed consent. Study participants are also free to withdraw from the 
trials at any time and for any reason. 
To assist participants in eliminating or reducing HIV risk behaviors, extensive counseling is provided at each study 
visit, and more often if needed. This interactive counseling has proven effective in reducing the risk of HIV and other 
STDs in multiple populations, including past participants in similar HIV prevention trials. Participants are also offered 
free condoms and STD testing and treatment to reduce their risk for HIV infection. The health of participants is closely 
monitored throughout each trial, and participants are linked to any necessary medical care.
To ensure that the studies remain on a solid scientific and ethical foundation, all study procedures and plans have been reviewed 
and approved by scientific and ethical review committees at CDC (called institutional review boards, or IRBs), as well as IRBs 
established by each host country and research site prior to trial launch. Additionally, data on safety, enrollment, and efficacy 
are reviewed regularly by an independent data safety and monitoring board (DSMB) for each trial. The boards review 
emerging data to ensure that continuing the trial is safe and to determine the point at which the results are conclusive. If 
scientific questions arise during the course of the research, the boards meet more frequently. CDC has worked closely with 
community partners at each research site to ensure active community participation throughout the course of the trial.
If the efficacy trial in Thailand proves that tenofovir is effective as PrEP for injection drug users, participants in that 
trial and their community will be the first to benefit. All trial participants will receive tenofovir for at least one year after 
efficacy is proven while CDC works with the Thai Food and Drug Administration for approval of use by the Thai health 
care system. CDC is also prepared to provide technical assistance and support to its international partners in designing 
PrEP implementation plans in those countries where CDC-sponsored trials are being conducted.
Other Ongoing PrEP Trials 
CDC Participation in Partners PrEP Study
The University of Washington is working with collaborators in Kenya and Uganda to conduct the Partners PrEP Study, which 
is examining the safety and efficacy of two different PrEP regimens — once-daily tenofovir and once-daily tenofovir plus 
emtricitabine — among heterosexual couples. CDC co-manages two trial sites in Uganda, in conjunction with The AIDS 
Support Organization (TASO), the largest indigenous non-governmental organization providing HIV care in Uganda. 
This randomized, double-blind, placebo-controlled study operates at nine trial sites in Kenya and Uganda and will include 
3,900 serodiscordant couples (couples in which one person is HIV-infected and the other is not). Stable serodiscordant 
couples are the largest risk group for HIV infection in Africa, and this trial will provide important data on whether PrEP 
could be used to prevent new HIV infections among this population. HIV-uninfected partners are assigned to one of three 
groups: tenofovir, tenofovir plus emtracitabine, or placebo. All participants receive ongoing risk reduction counseling and 
HIV testing, and their safety is monitored by the study’s DSMB and local IRBs. HIV-infected members of the discordant 
couples receive ongoing HIV care.
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The trial is the first to test the safety and efficacy of both tenofovir and tenofovir plus emtricitabine in the  
same population and will allow investigators to simultaneously evaluate the two drugs as candidates for  
use as PrEP.
Other PrEP Studies
Several other PrEP trials are being conducted by other sponsors. For detailed information on the full range of PrEP trials 
underway, visit www.avac.org.
PrEP Implementation Planning in the U.S.
The positive results from the iPrEx study have immediate implications for HIV prevention among gay and bisexual 
men the U.S., since tenofovir plus emtricitabine pills are already FDA-approved and available with a prescription for the 
treatment of HIV infection. As the agency responsible for protecting public health, CDC is pursuing two primary goals 
in the wake of the iPrEx trial findings: developing guidance on the safe and effective use of PrEP among MSM, and 
determining how to most effectively use PrEP in combination with other prevention strategies to reduce new infections 
among MSM in the U.S. 
When the iPrEx results were announced, CDC immediately provided initial cautions for anyone considering using PrEP, 
followed by more detailed interim clinical guidance for physicians electing to provide PrEP for HIV prevention among 
high-risk gay and bisexual men. For details, see CDC resources (available at http://www.cdc.gov/hiv/prep). 
r “Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: Promoting Safe and Effective Use in the United States” 
r “Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men” 
The next step is developing formal U.S. Public Health Service guidelines for PrEP, which CDC will lead in collaboration 
with other federal health agencies. The guidelines will be based on a full review of trial data and other research, and will 
incorporate input from providers, HIV prevention partners, and affected communities. The guidelines will help ensure 
both physicians and MSM considering PrEP have accurate information to guide decisions.
In addition to developing public health guidelines, CDC will be implementing a range of activities to promote the 
effective and strategic use of PrEP in the U.S., such as adapting national HIV surveillance systems to help evaluate the 
use and impact of PrEP, developing updated risk reduction messages for MSM that address PrEP and other proven HIV 
prevention strategies, and examining the costs, impact, and cost-effectiveness of PrEP compared to and in combination 
with other interventions. 
CDC has also identified other activities that could help address remaining research questions and is currently exploring all 
avenues to identify resources to support them. Key among these is the need for demonstration projects in clinics serving 
MSM to assess feasibility, acceptability, and the impact of PrEP in real-world settings.
As results from PrEP efficacy trials among injection drug users and heterosexuals become available, CDC will evaluate the 
study findings and determine appropriate next steps for PrEP implementation among those populations.
